Venous thrombosis in children

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 3, 2008, Pages 411-418

  Price, Victoria E ^a   Chan, Anthony K C ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulation; Diagnosis; Outcome; Pediatrics; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; ASPARAGINASE; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN; TISSUE PLASMINOGEN ACTIVATOR; VITAMIN K GROUP; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; CHILD; CHILDHOOD MORTALITY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPRESSION THERAPY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DOPPLER ECHOGRAPHY; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; JUGULAR VEIN; LEG THROMBOSIS; LOADING DRUG DOSE; LONG TERM CARE; LUNG EMBOLISM; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PHLEBOGRAPHY; POPULATION RESEARCH; POSTTHROMBOSIS SYNDROME; PRACTICE GUIDELINE; PREVALENCE; RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; THROMBECTOMY; THROMBOGENESIS; TREATMENT DURATION; TREATMENT OUTCOME; VEIN THROMBOSIS; AGE; CENTRAL VENOUS CATHETERIZATION; FEMALE; HOSPITALIZATION; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PROGNOSIS; RADIOGRAPHY; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADMINISTRATION, ORAL; AGE FACTORS; ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MALE; PHLEBOGRAPHY; PROGNOSIS; PULMONARY EMBOLISM; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 41449116039     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.3.411     Document Type: Review

References (77)

1. Andrew M, David M, Adams M et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 83(5), 1251-1257 (1994).
2. Coon WW, Willis PW 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 48(4), 839-846 (1973).
3. Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb. Haemost. 63(1), 27-30 (1990).
4. Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb. Haemost. 72(6), 836-842 (1994).
5. Nitschmann E, Berry L, Bridge S et al. Morphological and biochemical features affecting the antithrombotic properties of the aorta in adult rabbits and rabbit pups. Thromb. Haemost. 79(5), 1034-1040 (1998).
6. Kuhle S, Massicotte P, Chan A et al. Systemic thromboembolism in children. Data from the 1-800-NO-CLOTS Consultation Service. Thromb. Haemost. 92(4), 722-728 (2004).
7. Montes de Oca MA, Babron MC, Bletry O et al. Thrombosis in systemic lupus erythematosus: a French collaborative study. Arch. Dis. Child. 66(6), 713-717 (1991).
8. Berube C, Mitchell L, Silverman E et al. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Pediatr. Res. 44(3), 351-356 (1998).
9. Andrew M, Marzinotto V, Pencharz P et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J. Pediatr. 126(3), 358-363 (1995).
10. Marsh D, Wilkerson SA, Cook LN, Pietsch JB. Right atrial thrombus formation screening using two-dimensional echocardiograms in neonates with central venous catheters. Pediatrics 81(2), 284-286 (1988).
11. Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. J. Pediatr. 126(1), 50-54 (1995).
12. Beck C, Dubois J, Grignon A, Lacroix J, David M. Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J. Pediatr. 133(2), 237-241 (1998).
13. Male C, Chair P, Ginsberg JS et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb. Haemost. 87(4), 593-598 (2002).
14. Price VE, Carcao M, Connolly B et al. A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J. Thromb. Haemost. 2(5), 737-742 (2004).
15. Manco-Johnson MJ, Grabowski EF, Hellgreen M et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb. Haemost. 88(1), 157-158 (2002).
16. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 96(5 Pt 1), 939-943 (1995).
17. Berkun Y, Padeh S, Barash J et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 55(6), 850-855 (2006).
18. van Ommen CH, Heijboer H, van den Dool EJ, Hutten BA, Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J. Thromb. Haemost. 1(12), 2516-2522 (2003).
19. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J. Pediatr. 139(5), 676-681 (2001).
20. Bonduel M, Hepner M, Sciuccati G et al. Factor V Leiden and prothrombin gene G20210A mutation in children with venous thromboembolism. Thromb. Haemost. 87(6), 972-977 (2002).
21. Hagstrom JN, Walter J, Bluebond-Langner R, Amatniek JC, Manno CS, High KA. Prevalence of the factor V leiden mutation in children and neonates with thromboembolic disease. J. Pediatr. 133(6), 777-781 (1998).
22. Lawson SE, Butler D, Enayat MS, Williams MD. Congenital thrombophilia and thrombosis: a study in a single centre. Arch. Dis. Child. 81(2), 176-178 (1999).
23. Heller C, Becker S, Scharrer I, Kreuz W. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur. J. Pediatr. 158 Suppl 3 S117-121 (1999).
24. Nowak-Gottl U, Junket R, Kreuz W et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 97(4), 858-862 (2001).
25. Vossen CY, Conard J, Fontcuberta J et al. Risk of a first venous thrombotic event in carriers of a Familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J. Thromb. Haemost. 3(3), 459-464 (2005).
26. David M, Manco-Johnson M, Andrew M. Diagnosis and treatment of venous thromboembolism in children and adolescents. On behalf of the Subcommittee on Perinatal Haemostasis of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 74(2), 791-792 (1995).
27. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann. Intern. Med. 128(8), 663-677 (1998).
28. Cogo A, Lensing AW, Wells P, Prandoni P Buller HR. Noninvasive objective tests for the diagnosis of clinically suspected deepvein thrombosis. Haemostasis 25(1-2), 27-39 (1995).
29. Mantoni M. Diagnosis of deep venous thrombosis by duplex sonography. Acta Radiol. 30(6), 575-579 (1989).
30. Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur. Radiol. 17(1), 175-181 (2007).
31. Das M, Muhlenbruch G, Mahnken AH et al. Optimized image reconstruction for detection of deep venous thrombosis at multidetector-row CT venography. Eur. Radiol. 16(2), 269-275 (2006).
32. Goodman LR, Stein PD, Matta F et al. CT venography and compression sonography are diagnostically equivalent: data from PIOPED II. AJR Am. J. Roentgenol. 189(5), 1071-1076 (2007).
33. Marsh JD, Glynn M, Torman HA. Pulmonary angiography. Application in a new spectrum of patients. Am. J. Med. 75(5), 763-770 (1983).
34. Zuckerman DA, Sterling KM, Oser RF. Safety of pulmonary angiography in the 1990s. J. Vasc. Interv. Radiol. 7(2), 199-205 (1996).
35. Worsley DF, Alavi A. Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study. J. Nucl. Med. 36(12), 2380-2387 (1995).
36. Lombard J, Bhatia R, Sala E. Spiral computed tomographic pulmonary angiography for investigating suspected pulmonary embolism: clinical outcomes. Can. Assoc. Radiol. J. 54(3), 147-151 (2003).
37. Stein PD, Fowler SE, Goodman LR et al. Multidetector computed tomography for acute pulmonary embolism. N. Engl. J. Med. 354(22), 2317-2327 (2006).
38. Babyn PS, Gahunia HK, Massicotte R Pulmonary thromboembolism in children. Pediatr. Radiol. 35(3), 258-274 (2005).
39. Monagle P, Chan A, Massicorte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.), 645S-687S (2004).
40. Newall F, Barnes C, Savoia H, Campbell J, Monagle P. Warfarin therapy in children who require long-term total parenteral nutrition. Pediatrics 112(5), e386 (2003).
41. Keaton C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340(12), 901-907 (1999).
42. Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol. Cell. Biochem. 48(3), 161-182 (1982).
43. Casu B, Oreste P, Torri G et al. The structure of heparin oligosaccharide fragments with high anti-(Factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nudear-magnetic-resonance studies. Biochem. J. 197(3), 599-609 (1981).
44. Andrew M, Marzinotto V, Massicotte P et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr. Res. 35(1), 78-83 (1994).
45. Bidlingmaier C, Magnani HN, Girisch M, Kurnik K. Safety and efficacy of danaparoid (Orgaran) use in children. Acta Daematol. 115(3-4), 237-247 (2006).
46. Sackler JP, Liu L. Heparin-induced osteoporosis. Br J. Radiol. 46(547), 548-550 (1973).
47. Murphy MS, John PR, Mayer AD, Buckels JA, Kelly DA. Heparin therapy and bone fractures. Lancet 340(8827), 1098 (1992).
48. Hirsh J, Levine MN. Low molecular weight heparin. Blood 79(1), 1-17 (1992).
49. Kuhle S, Massicotte P, Dinyari M et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb. haemost. 94(6), 1164-1171 (2005).
50. Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch. Dis. Child Fetal Neonatal Ed. 88(5), F365-370 (2003).
51. Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Pharmacotherapy 27(9), 1263-1271 (2007).
52. Andrew M, Paes B, Johnston M. Development of the hemostatic system in die neonate and young infant. Am. J. Pediatr. Hematol. Oncol. 12(1), 95-104 (1990).
53. Whidon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 17(8), 1371-1377 (1978).
54. Choonara. IA, Malia RG, Haynes BP et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br. J. Clin. Pharmacol. 25(1), 1-7 (1988).
55. Furie B, Furie BC. Molecular basis of vitamin K-dependent γ-carboxylation. Blood 75(9), 1753-1762 (1990).
56. Streif W, Andrew M, Marzinotto V et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 94(9), 3007-3014 (1999).
57. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann. Intern. Med. 121(9), 676-683 (1994).
58. Shearer MJ, Rahim S, Barkhan P. Stimmler L. Plasma vitamin K1 in mothers and their newborn babies. Lancet 2(8296), 460-463 (1982).
59. Greer FR, Mummah-Schendel LL, Marshall S, Sortie JW. Vitamin K1 (phylloquinone) and vitamin K2 (menaquinone) status in newborns during the first week of life. Pediatrics 81(1), 137-140 (1988).
60. Haroon Y, Shearer MJ, Rahim S, Gunn WG, McEnery G, Barkhan P. The content of phylloquinone (vitamin K1) in human milk, cows' milk and infant formula foods determined by high-performance liquid chromatography. J. Nutr. 112(6), 1105-1117 (1982).
61. von Kries R, Shearer M, McCarthy PT, Haug M, Harzer G, Gobel U. Vitamin K1 content of maternal milk: influence of the stage of lactation, lipid composition, and vitamin K1 supplements given to the mother. Pediatr. Res. 22(5), 513-517 (1987).
62. Severijnen R, Bayat N, Bakker H, Tolboom J, Bongaerts G. Enteral drug absorption in patients with short small bowel: a review. Clin. Pharmacokinet. 43(14), 951-962 (2004).
63. Marzinotto V, Monagle P, Chan A et al. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr. Cardiol. 21(4), 347-352 (2000).
64. Newall F, Monagle P, Johnston L. Home INR monitoring of oral anticoagulant therapy in children using the CoaguChek S point-of-care monitor and a robust education program. Thromb. Res. 118(5), 587-593 (2006).
65. Ignjatovic V, Barnes C, Newall F, Hamilton S, Burgess J, Monagle P. Point of care monitoring of oral anticoagulant therapy in children: comparison of CoaguChek Plus and Thrombotest methods with venous international normalised ratio. Thromb. Haemost. 92(4), 734-737 (2004).
66. Barnes C, Newall F, Ignjatovic V et al. Reduced bone density in children on long-term warfarin. Pediatr. Res. 57(4), 578-581 (2005).
67. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl), 265S-286S (2004).
68. Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J. Pediatr Hematol. Oncol. 28(1), 4-10 (2006).
69. Almond CS, Harrington J, Thiagarajan R et al. Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. J. Heart Lung Transplant. 25(11), 1376-1379 (2006).
70. Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J. Thromb. Haemost. 5(8), 1654-1659 (2007).
71. Young G, Boshkov LK. Prospective study of direct thrombin inhibition with argatfoban in pediatric patients requiring nonheparin-anticoagulation. Presented at: 49th Annual Meeting of the American Society of Hematology.Atlanta, GA, USA, 8 December-11 December 2007.
72. Herbert J M, Herault JP, Bernat A et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91(11), 4197-4205 (1998).
73. Albisetti M. Thrombolytic therapy in children. Thromb. Res. 118(1), 95-105 (2006).
74. Monagle P, Adams M, Mahoney M et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr. Res. 47(6), 763-766 (2000).
75. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N. Engl. J. Med. 351(11), 1081-1088 (2004).
76. Rutherford RB. Pathogenesis and pathophysiology of the post-thrombotic syndrome: clinical implications. Semin. Vasc. Surg. 9(1), 21-25 (1996).
77. Kuhle S, Koloshuk B, Marzinotto V et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb. Res. 111(4-5), 227-233 (2003).